Press "Enter" to skip to content

Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies

  • Zynerba Pharmaceuticals Inc (NASDAQ: ZYNEpresents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD).
  • Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.
  • The treatment was associated with improved sleep in children with clinically significant sleep disorders at baseline.
  • Furthermore, the children with both DEE and autism spectrum disorder (ASD) showed more wide-ranging sleep benefits than those with DEE alone.
  • In patients with ASD (n=5), improvements compared to baseline were observed over the 26-week study period in sleep breathing, sleep-wake transition, and the total sleep disturbance scale for children.
  • In patients without ASD (n=11), improvement was seen in initiating and maintaining sleep.
  • Zygel was well tolerated. Most treatment-emergent adverse events were characterized as mild or moderate.
  • Over the 26-week study period, 60.4% of participants had more than one related adverse event, with 93% mild/moderate severity.
  • Price Action: ZYNE shares are up 2.95% at $5.58 during the market session on the last check Friday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *